
Sucrobind 500mg Chewable Tablet
Marketer
La Renon Healthcare Pvt Ltd
Salt Composition
Sucroferric oxyhydroxide (500mg)
Overview Sucrobind 500mg Chewable Tablet
Lanthanum Carbonate 500mg Chewable Tablets are prescribed to manage elevated blood phosphate. This medication reduces phosphate levels, mitigating complications associated with hyperphosphatemia, especially in dialysis patients with impaired phosphate excretion. Administer these tablets with food, adhering to the doctor's prescribed schedule for consistent, evenly spaced doses. Dosage and treatment duration vary depending on individual needs. Abrupt cessation should be avoided; continue as directed for optimal results. Common side effects include altered stool color and diarrhea. Report any bothersome side effects or other symptoms to your physician for management options. Prior to commencing treatment, disclose all existing medical conditions and concurrent medications to your doctor. While generally safe during pregnancy and breastfeeding, physician consultation is recommended before use.
Primary Ingredients of Sucrobind 500mg Chewable Tablet
No text provided to rephrase.
Uses of Sucrobind 500mg Chewable Tablet
Managing elevated serum phosphorus concentrations
Major Benefits of Sucrobind 500mg Chewable Tablet:
Follow your physician's instructions or consult the product label for guidance. Administer this medication orally. Ensure complete mastication before ingestion, unless otherwise specified by your doctor. Consume Sucrobind 500mg Chewable Tablets with a meal.
Common Side effects of Sucrobind 500mg Chewable Tablet:
- Discoloration of stool
- Diarrhea
- Nausea
- Taste change
How to use Sucrobind 500mg Chewable Tablet:
Follow your physician's instructions or consult the product label for proper administration. Ingest this medication orally. Ensure complete mastication before swallowing, unless otherwise specified by your doctor. Consume Sucrobind 500mg Chewable Tablets with a meal.
How Sucrobind 500mg Chewable Tablet works:
Each Sucrobind 500mg chewable tablet delivers sucroferric oxyhydroxide, a non-calcium phosphate binder derived from iron. Administered with meals, it attaches to dietary phosphate within the digestive system, inhibiting its absorption into the bloodstream and thus managing elevated blood phosphate levels.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Sucrobind 500mg Chewable Tablets may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Chewing Sucrobind 500mg tablets is contraindicated during pregnancy due to established risks to the fetus. Exceptions may be made in life-threatening circumstances where a physician deems the potential benefits outweigh the hazards. Physician consultation is essential.
Breast feedingCONSULT YOUR DOCTOR
The use of Sucrobind 500mg Chewable Tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Sucrobind 500mg Chewable Tablets on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Chewable Sucrobind 500mg tablets are considered safe for use in individuals with kidney impairment. No alteration of the Sucrobind 500mg chewable tablet dosage is necessary.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding Sucrobind 500mg Chewable Tablet use in individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Sucrobind 500mg Chewable Tablet :
Should you forget to take a Sucrobind 500mg Chewable Tablet, ingest it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Sucrobind 500mg Chewable Tablet
| Label | Value |
|---|---|
| Chemical Type | Glycoconjugates with O-linked glycosylation |
| Developing Habits | No. |
| Treatment Category | KINSHIP |
